ASX Announcement
23 June 2026

General Meeting to Convene on Friday, 24 July 2026

The general meeting (**General Meeting**) of Microba Life Sciences Limited (ASX : MAP) (**Microba** or **Company**) is scheduled to be held on Friday, 24 July 2026 at 1:00pm AEST (Brisbane time).

The Letter to Shareholders, Notice of General Meeting and Proxy Form dispatched to Shareholders are **attached**.

View this announcement on our Investor Hub: https://ir.microba.com/link/PGXOzy

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com

23 June 2026

Dear Shareholder,

Invitation to Microba Life Sciences' General Meeting

On behalf of the Board of Directors of Microba Life Sciences Limited (**Microba**), I am pleased to invite you to the General Meeting of Microba (**General Meeting**).

Following the support already received from shareholders, alongside new and existing institutional and sophisticated investors through the $5.0 million placement (**Placement**), we are now seeking to broaden participation through a $1.0 million Share Purchase Plan (**SPP**). Eligible shareholders will receive a Prospectus, SPP invitation and Target Market Determination to participate in the SPP. The Prospectus and Target Market Determination should be read in their entirety before making any investment decision.

Proceeds raised under the Placement and SPP will be used to fund Microba's path to break-even. More specifically, the proceeds will be used for:

- Core diagnostics growth across Australia and the UK;
- Delivery of a category-defining new testing product;
- Strengthening working capital; and
- Costs of the Placement and SPP.

The General Meeting will be held at Thomsons, Level 28, 1 Eagle Street, Brisbane on Friday, 24 July 2026 at 1:00pm AEST (Brisbane time).

Lodging Your Proxy and Questions

We encourage you to lodge a directed proxy form by 1:00pm AEST (Brisbane time) on Wednesday, 22 July 2026 if you are unable to attend the General Meeting in person. In addition, please submit any questions ahead of the General Meeting to give our management team the best opportunity to address them comprehensively during the General Meeting. Full details on how to participate, either in person or by proxy, can be found in the attached Notice of General Meeting & Explanatory Statement.

Access to General Meeting Documents

The Notice of General Meeting & Explanatory Statement can be viewed and downloaded from: https://ir.microba.com/announcements.

Shareholders who have nominated an email address, and have elected to receive electronic communications from the Company, will receive an email to their nominated email address with a link to an electronic copy of the important General Meeting documents.

In accordance with sections 110C-110H and 110J-110K of the *Corporations Act 2001* (Cth), no hard copy of the Notice of General Meeting & Explanatory Statement will be circulated, unless a shareholder has requested a hard copy.

If you are unable to access any of the important General Meeting documents online or if you wish to receive a hard copy of the General Meeting documents please contact our share registry, Automic, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) or via email at corporate.actions@automicgroup.com.au.

Microba will no longer send a hard copy of General Meeting documents unless a shareholder requests a copy to be mailed.

We encourage all shareholders to provide an email address so that we can send investor communications electronically when they become available online, which includes items such as meeting documents.

23 June 2026

Stay Informed — Join the Microba Investor Hub

To ensure you're receiving timely company email updates, ASX announcements & invitations to investor webinars, we encourage all shareholders to activate their Microba Investor Hub profile.

With your Microba Investor Hub profile, you can:

- Access company news, market updates and ASX announcements
- Stay informed about exclusive investor webinars and events
- Engage directly with the Microba team through Q&A

Activate your profile today at https://ir.microba.com/ or simply scan the QR code.

Shareholders can still elect to receive some or all of their communications in hard copy or electronic form or elect not to receive certain documents such as annual reports in hard copy.

Updating Your Communication Preferences

To ensure that you receive important updates efficiently, we encourage all shareholders to provide an email address for electronic communications, which includes notices, meeting documents, and annual reports. You can update your communication preferences at https://investor.automic.com.au/.

If you are a shareholder and would like a hard copy of a communication, need further information about the options available to you or have questions about your holding, visit https://investor.automic.com.au/ or contact our share registry, Automic, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia) or via email at corporate.actions@automicgroup.com.au.

Thank you for your continued support of Microba.

Yours sincerely,

Pasquale Rombola
Chair | Microba Life Sciences Limited

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com

https://ir.microba.com/welcome

About Microba Life Sciences Limited
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com

Microba Life Sciences Limited
ACN 617 096 652

Notice of General Meeting & Explanatory Statement

To be held at:	Thomsons, Level 28, 1 Eagle Street, Brisbane QLD 4000
To be held on:	Friday, 24 July 2026
Commencing at:	1:00pm AEST (Brisbane time)

Important Information
This Notice of General Meeting & Explanatory Statement should be read in its entirety. If Shareholders are in doubt as to how they should vote, they should seek advice from their professional advisers prior to voting.

Stay Informed — Join the Microba Investor Hub

To ensure you're receiving timely company email updates, ASX announcements & invitations to investor webinars, we encourage all shareholders to activate their Microba Investor Hub profile.

With your Microba Investor Hub profile, you can:
- Access company news, market updates and ASX announcements
- Stay informed about investor webinars and events
- Engage directly with the Microba team through Q&A

Activate your profile today at https://ir.microba.com/ or simply scan the QR code.

Important dates

Issue date of the Tranche 1 Placement Shares	18 June 2026
Deadline for lodgement of Proxy Forms for the General Meeting	1:00pm AEST (Brisbane time), 22 July 2026
General Meeting	1:00pm AEST (Brisbane time), 24 July 2026
Anticipated issue date of the: • Tranche 2 Placement Shares • Placement Options • SPP Shares • SPP Options • Broker Options	29 July 2026

*Dates are indicative only and subject to change. The occurrence of milestones after the General Meeting are conditional on the passing of the Resolutions at the General Meeting.

Letter from the Chair

Dear Shareholders,

General Meeting

We are pleased to invite you to the General Meeting of Microba Life Sciences Limited ACN 617 096 652 (**Company**) to be held at 1:00pm AEST (Brisbane time) on Friday, 24 July 2026 at Thomsons, Level 28, 1 Eagle Street, Brisbane QLD 4000 (**General Meeting**).

Following the strong support we've received from Shareholders, alongside new and existing institutional and sophisticated investors through the $5.0 million Placement, we are now seeking to broaden participation through a $1.0 million non-underwritten Share Purchase Plan (**SPP**).

Proceeds raised under the Placement will be used to fund Microba's path to break-even. More specifically, the proceeds of the Placement will be used for:

- Core diagnostics growth across Australia and the UK;
- Delivery of a category-defining new testing product;
- Strengthening working capital; and
- Costs of the Placement and SPP.

Proceeds raised under the SPP will be used for working capital requirements.

Votes may be submitted during the General Meeting only by those Shareholders physically in attendance at the General Meeting either in person or through a validly appointed corporate representative. Votes via validly submitted Proxy Forms will also be accepted.

In accordance with Part 1.2AA of the *Corporations Act 2001 (Cth)*, the Company will only be dispatching physical copies of the Notice of General Meeting & Explanatory Statement to Shareholders who have elected to receive notices of meeting in physical form. The Notice of General Meeting & Explanatory Statement is being made available to Shareholders electronically and can be viewed and downloaded online at the Company's Investor Relations Website https://ir.microba.com/ announcements page.

We encourage all Shareholders to activate their profile and link their shareholding on Microba's Investor Hub platform at https://ir.microba.com/ to ensure they are receiving the most up-to-date information from the Company. Investor Hub is our dedicated shareholder engagement platform, providing access to company ASX announcements, Q&A with Company management, access to investor emails as well as invitations to exclusive investor webinars. By registering, you'll stay informed about Microba's broader strategic and commercial progress as we continue to scale across key markets.

Background to the Resolutions

On 12 June 2026, the Company announced the following:

(a) The Company had received firm commitments for a placement of 100,004,240 new fully-paid ordinary shares in the Company, to sophisticated, professional and institutional investors, at a price of $0.05 per Share (**Placement**) to raise approximately $5.0 million (before costs).

(b) Additionally, the Company will offer a share purchase plan (**SPP**), to a cap of $1.0 million, to existing Eligible Shareholders at a price of $0.05 per Share to raise a further $1.0 million (before costs) on the same terms as the Placement.

(c) Under both the Placement and the SPP, the Company will offer one (1) free attaching Option for every one (1) new Share subscribed for. Such Options will have an exercise price of $0.0625 per Option and will expire 3 years following their issue.

The Shares issued under the Placement (**Placement Shares**) are to be issued in two tranches:

(a) 91,344,455 Placement Shares were issued on 18 June 2026 (**Tranche 1 Placement Shares**); and

(b) 8,659,785 Placement Shares are proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting (**Tranche 2 Placement Shares**).

The Options to be issued under the Placement (**Placement Options**) are proposed to be issued as follows:

(a) 91,344,455 Placement Options which were free attaching to the Tranche 1 Placement Shares are proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting (**Tranche 1 Placement Options**). In the event Shareholder approval is not provided for the Tranche 1 Placement Options, the Tranche 1 Placement Options will not be issued; and

(b) 8,659,785 Placement Options which are free attaching to the Tranche 2 Placement Shares are proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting (**Tranche 2 Placement Options**).

It is proposed that the Shares (**SPP Shares**) and the Options (**SPP Options**) to be issued under the SPP will be issued on 29 July 2026, following receipt of Shareholder approval at the General Meeting.

All Tranche 2 Placement Shares and Tranche 2 Placement Options proposed to be issued to a Related Party of the Company, are subject to Shareholder approval.

Purpose of General Meeting

This General Meeting seeks the approval of Shareholders for:

The Placement:

(a) Resolution 1 seeks Shareholder approval for the ratification of the issue of the Tranche 1 Placement Shares under ASX Listing Rule 7.4;

(b) Resolution 2 seeks Shareholder approval for the issue of the Tranche 2 Placement Shares under ASX Listing Rule 7.1;

(c) Resolution 3 seeks Shareholder approval for the issue of the free attaching Placement Options (consisting of the Tranche 1 Placement Options and Tranche 2 Placement Options) pursuant to the Placement under ASX Listing Rule 7.1;

(d) Resolution 4(a) seeks Shareholder approval for the issue of a number of the Tranche 2 Placement Shares to Mr Pasquale Rombola, a Director, under ASX Listing Rule 10.11. These Tranche 2 Placement Shares are being issued on the same terms as the Tranche 1 Placement Shares and Tranche 2 Placement Shares under the Placement;

(e) Resolution 4(b) seeks Shareholder approval for the issue of a number of the Tranche 2 Placement Options to Mr Pasquale Rombola, a Director, under ASX Listing Rule 10.11. These Tranche 2 Placement Options are being issued on the same terms as the Tranche 1 Placement Options and Tranche 2 Placement Options under the Placement;

(f) Resolution 5(a) seeks Shareholder approval for the issue of a number of the Tranche 2 Placement Shares to Professor Ian Frazer, a Director, under ASX Listing Rule 10.11. These Tranche 2 Placement Shares are being issued on the same terms as the Tranche 1 Placement Shares and Tranche 2 Placement Shares under the Placement;

(g) Resolution 5(b) seeks Shareholder approval for the issue of a number of the Tranche 2 Placement Options to Professor Ian Frazer, a Director, under ASX Listing Rule 10.11. These Tranche 2 Placement Options are being issued on the same terms as the Tranche 1 Placement Options and Tranche 2 Placement Options under the Placement;

The SPP:

(h) Resolution 6(a) seeks Shareholder approval for the issue of the SPP Shares pursuant to the SPP under ASX Listing Rule 7.1;

(i) Resolution 6(b) seeks Shareholder approval for the issue of the SPP Options pursuant to the SPP under ASX Listing Rule 7.1; and

Broker Options:

(j) Resolution 7 seeks Shareholder approval for the issue of the Broker Options under ASX Listing Rule 7.1,

(together, the **Resolutions**).

Capital structure

The following table details the projected capital structure of the Company after completion of the Placement and SPP and issue of the Broker Options (on an undiluted basis).

Current capital structure[1]	
Issued capital of the Company prior to completion of the Placement and SPP and issue of the Broker Options	608,963,034 Shares 150,634,797 Options
Placement	
Issue of Tranche 1 Placement Shares	91,344,455 Shares
Issue of Tranche 2 Placement Shares (following Shareholder approval)	8,659,785 Shares
Issue of Tranche 1 Placement Options and Tranche 2 Placement Options (following Shareholder approval)	100,004,240 Options
SPP	
Issue of SPP Shares (to all Eligible Shareholders) (following Shareholder approval)	20,000,000 Shares
Issue of SPP Options (to all Eligible Shareholders) (following Shareholder approval)	20,000,000 Options
Broker Options	
Issue of Broker Options	8,089,672 Options
Projected issued capital after completion of the Placement and SPP and assuming the SPP is subscribed to $1.0 million and all Options are issued (but not exercised)	**728,967,274 Shares** **278,728,709 Options**

1. *The "current" capital structure shown above is stated on a pre-Placement basis. It does not include the 91,344,455 Tranche 1 Placement Shares, which were issued on 18 June 2026. As at the date of this Notice, the Company has 700,307,489 Shares on issue.*

Voting

A Shareholder can vote either in person or by proxy.

Shareholders are encouraged to vote online at portal.automic.com.au/investor.

Alternatively, the attached proxy form can be returned by:

Post to:	Automic GPO Box 5193 Sydney NSW 2001
Or email to:	meetings@automicgroup.com.au
Or in person:	Automic Level 5, 126 Phillip Street Sydney NSW 2000
Or fax to:	02 8583 3040 within Australia or +61 2 8583 3040 outside Australia

If you are unsure as to how to vote, we recommend that you speak with your professional adviser.

Booklet

With respect to the General Meeting, this booklet contains the following:

- The Notice of General Meeting for the General Meeting which contains information about the business to be conducted at the General Meeting, including the Resolutions to be put to the Shareholders (see Part B).
- Information explaining the business to be conducted at the General Meeting (see the Explanatory Statement at Part D).
- Information on how to vote, how to attend the General Meeting and how to appoint a proxy to vote on the Resolutions to be passed at the General Meeting (see Part C).

Questions

Should you wish to discuss the matters in this Notice of General Meeting & Explanatory Statement, please do not hesitate to contact the Company Secretary, James Heath at James.Heath@microba.com. Alternatively, you should consult your licensed financial adviser, stockbroker or other professional adviser.

If you have any questions in regards to your holding in Shares or other Share registry matters, please consult Automic on 1300 288 664 (from within Australia) and +61 2 9698 5414 (from outside Australia). We look forward to the participation of all Shareholders at the General Meeting on 1:00pm (Brisbane time) on 24 July 2026.

We appreciate your continued support and look forward to welcoming you to the General Meeting.

Yours sincerely,

Pasquale Rombola | Chair - Microba Life Sciences Limited

Section A – Glossary

$	Australian dollars.
General Meeting	The meeting of Shareholders convened by the Notice of General Meeting & Explanatory Statement.
ASIC	The Australian Securities & Investments Commission.
ASX	The Australian Securities Exchange operated by ASX Limited.
Board	The board of Directors of the Company.
Business Day	Monday to Friday inclusive, except any day that the ASX declares is not a business day.
Chairman or **Chair**	The Chair of the General Meeting.
Company or **Microba**	Microba Life Sciences Limited ACN 617 096 652.
Corporations Act	The *Corporations Act 2001* (Cth) for the time being in force together with the *Corporations Regulations 2001* (Cth).
Directors	The directors of the Company.
Equity Securities	Any type of security, including a share, option, unit, convertible security, and as otherwise defined in the ASX Listing Rules.
Eligible Shareholder	Has the meaning given to that term in the prospectus for the SPP.
Explanatory Statement	The information set out in **Section D** of this Notice of General Meeting & Explanatory Statement.
Glossary	The glossary contained in this **Section A** of this Notice of General Meeting & Explanatory Statement.
Joint Lead Managers	Morgans Corporate Limited and Canaccord Genuity (Australia) Limited.
Listing Rules or **ASX Listing Rules**	The listing rules of ASX, as amended from time to time.
Notice of General Meeting	The Notice of General Meeting contained in **Section B** of this Notice of General Meeting & Explanatory Statement.
Notice of General Meeting & Explanatory Statement	This Notice of General Meeting & Explanatory Statement, including the Notice of General Meeting, Explanatory Statement, the schedules and the Proxy Form.
Option	An option to subscribe for a Share in the Company.
Placement	A placement of 100,004,240 new fully-paid ordinary shares in the Company, to sophisticated, professional and institutional investors, at a price of A$0.05 per Placement Share to raise approximately A$5.0 million (before costs) together with one free attaching Placement Option exercisable at $0.0625 each on or before the date that is 3 years following their issue for every one Placement Share issued.
Placement Options	An Option offered under the Placement (one free attaching Placement Option for every one Placement Share) exercisable at $0.0625 per Option on or before the date that is 3 years following issue of the Placement Option. The terms of which are detailed in **Schedule 1**. The Placement Options consist of the Tranche 1 Placement Options and the Tranche 2 Placement Options.
Placement Shares	The Tranche 1 Placement Shares and the Tranche 2 Placement Shares.
Proxy Form	The proxy form accompanying the Notice of General Meeting & Explanatory Statement.
Related Party or **Parties**	Has the meaning given to that term in the Listing Rules.
Resolutions	The resolutions set out in the Notice of General Meeting and **Resolution** means any of them.
Section	A section of this Notice of General Meeting & Explanatory Statement.

Shareholder	A holder of one or more Shares.
Shares	The ordinary shares on issue in the share capital of the Company and **Share** means any one of them.
Broker Options	The 8,089,672 Options exercisable at $0.0750 per Broker Option on or before the date that is 3 years following the issue of the Broker Option. The terms of the Broker Options are detailed in **Schedule 2**.
SPP	The offer to each Eligible Shareholder to subscribe for up to $30,000 of SPP Shares at an issue price of $0.05 per Share with one free attaching SPP Option for every one SPP Shares issued, exercisable at $0.0625 each on or before the date that is 3 years following their issue, to raise up to $1.0 million before costs.
SPP Options	An Option offered under the SPP (one free attaching SPP Option for every one SPP Share subscribed for) exercisable at $0.0625 per SPP Option on or before the date that is 3 years following the issue of the SPP Option. The terms of which are detailed in **Schedule 1.**
SPP Shares	A Share offered under the SPP at an issue price of $0.05 per Share.
Tranche 1 Placement	Means the placement of the Tranche 1 Placement Shares and Tranche 1 Placement Options.
Tranche 1 Placement Options	Means the 91,344,455 Placement Options which were free attaching to the Tranche 1 Placement Shares, proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting.
Tranche 1 Placement Shares	Means the 91,344,455 Shares issued on 18 June 2026 as part of the Placement.
Tranche 2 Placement	Means the placement of the Tranche 2 Placement Shares and Tranche 2 Placement Options.
Tranche 2 Placement Options	Means the 8,659,785 Placement Options which are free attaching to the Tranche 2 Placement Shares proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting.
Tranche 2 Placement Shares	Means the 8,659,785 Shares proposed to be issued on or around 29 July 2026, subject to receiving Shareholder approval at the General Meeting, as part of the Placement.

Section B – Notice of General Meeting

Time and place

Notice is hereby given that the General Meeting will be held as follows:

Held at:	Thomsons, Level 28, 1 Eagle Street, Brisbane City QLD 4000
Commencing at:	1:00pm AEST (Brisbane time) on Friday, 24 July 2026

Voting

Votes may be submitted during the General Meeting only by those Shareholders physically in attendance at the General Meeting or through a validly appointed corporate representative. Votes via validly submitted Proxy Forms will also be accepted. **Accordingly, the Company strongly encourages Shareholders to lodge a directed Proxy Form with the Company no later than 48 hours prior to the General Meeting.**

Explanatory Statement

The Explanatory Statement which accompanies and forms part of this Notice of General Meeting describes the matters to be considered at the General Meeting.

Defined terms

Terms used in this Notice of General Meeting have the meaning given to them in the Glossary in **Section A** of this Notice of General Meeting & Explanatory Statement in which this Notice of General Meeting is contained.

SPECIAL BUSINESS

1. Resolution 1: Ratification of Tranche 1 Placement Shares issued under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the Company's prior issue of 91,344,455 Tranche 1 Placement Shares issued under Listing Rule 7.1 at an issue price of $0.05 per Tranche 1 Placement Share on the terms and conditions set out in the Explanatory Statement."

Short explanation

On 18 June 2026, the Company issued 91,344,455 Tranche 1 Placement Shares to sophisticated and professional investors at an issue price of $0.05 per Tranche 1 Placement Share.

Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period (**15% Placement Capacity**).

The 91,344,455 Tranche 1 Placement Shares were issued within the 15% Placement Capacity. Approval under ASX Listing Rule 7.4 is being sought to ratify the issue of the Tranche 1 Placement Shares and re-set the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- any person who participated in the issue of the Tranche 1 Placement Shares; or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

2. Resolution 2: Authority to issue Tranche 2 Placement Shares under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve and authorise the Company to issue 8,659,785 Tranche 2 Placement Shares at an issue price of $0.05 per Tranche 2 Placement Share on the terms and conditions set out in the Explanatory Statement."

Short explanation: The Company will (subject to Shareholder approval) issue the 8,659,785 Tranche 2 Placement Shares to sophisticated and professional investors at an issue price of $0.05 per Tranche 2 Placement Share.

Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12-month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12-month period (**15% Placement Capacity**).

Approval under ASX Listing Rule 7.1 is being sought as the number of Tranche 2 Placement Shares exceeds the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- a person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

3. Resolution 3: Authority to issue Placement Options (consisting of the Tranche 1 Placement Options and Tranche 2 Placement Options) under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve and authorise the Company to issue up to 100,004,240 Placement Options and, upon exercise of those Placement Options, the acquisition of the ordinary shares underlying those Placement Options, on the terms and conditions set out in the Explanatory Statement."

Short explanation

The Company will (subject to Shareholder approval) issue the Placement Options to sophisticated and professional investors at an exercise price of $0.0625 per Placement Option to be exercised on or before the date that is 3 years following their issue.

Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12 month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12 month period (**15% Placement Capacity**).

Approval under ASX Listing Rule 7.1 is being sought as the number of Placement Options exceeds the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- a person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

4. Resolution 4(a): Authority to issue Tranche 2 Placement Shares to a Related Party, Mr Pasquale Rombola, under ASX Listing Rule 10.11

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, the Company be authorised to issue up to 1,250,000 of the Tranche 2 Placement Shares to Mr Pasquale Rombola (or his nominee), a Director of the Company, on the terms and conditions set out in the Explanatory Statement."

Short explanation

This Resolution is required under ASX Listing Rule 10.11 to allow the issue of Equity Securities, being the 1,250,000 Tranche 2 Placement Shares, to Mr Pasquale Rombola (or his nominee), being a Director.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- Mr Pasquale Rombola (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
    - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
    - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

5. Resolution 4(b): Authority to issue Tranche 2 Placement Options to a Related Party, Mr Pasquale Rombola, under ASX Listing Rule 10.11

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, the Company be authorised to issue up to 1,250,000 of the Tranche 2 Placement Options to Mr Pasquale Rombola (or his nominee), a Director of the Company, and, upon exercise of those Tranche 2 Placement Options, the acquisition of the ordinary shares underlying those Tranche 2 Placement Options, on the terms and conditions set out in the Explanatory Statement."

Short explanation

This Resolution is required under ASX Listing Rule 10.11 to allow the issue of Equity Securities, being the 1,250,000 Tranche 2 Placement Options, to Mr Pasquale Rombola (or his nominee), being a Director.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- Mr Pasquale Rombola (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

6. Resolution 5(a): Authority to issue Tranche 2 Placement Shares to a Related Party, Professor Ian Frazer, under ASX Listing Rule 10.11

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, the Company be authorised to issue up to 200,000 of the Tranche 2 Placement Shares to Professor Ian Frazer (or his nominee), a Director of the Company, on the terms and conditions set out in the Explanatory Statement."

Short explanation

This Resolution is required under ASX Listing Rule 10.11 to allow the issue of Equity Securities, being the 200,000 Tranche 2 Placement Shares, to Professor Ian Frazer (or his nominee), being a Director.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- Professor Ian Frazer (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

7. Resolution 5(b): Authority to issue Tranche 2 Placement Options to a Related Party, Professor Ian Frazer, under ASX Listing Rule 10.11

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of ASX Listing Rule 10.11 and for all other purposes, the Company be authorised to issue up to 200,000 of the Tranche 2 Placement Options to Professor Ian Frazer (or his nominee), a Director of the Company, and, upon exercise of those Tranche 2 Placement Options, the acquisition of the ordinary shares underlying those Tranche 2 Placement Options, on the terms and conditions set out in the Explanatory Statement."

Short explanation

This Resolution is required under ASX Listing Rule 10.11 to allow the issue of Equity Securities, being the 200,000 Tranche 2 Placement Options, to Professor Ian Frazer (or his nominee), being a Director.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- Professor Ian Frazer (or his nominee) and any other person who will obtain a material benefit as a result of the issue of the securities (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

8. Resolution 6(a): Authority to issue SPP Shares under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, conditional on the approval of Resolution 6(b), for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve and authorise the Company to issue up to 20,000,000 SPP Shares at an issue price of $0.05 per SPP Share, on the terms and conditions set out in the Explanatory Statement."

Short explanation

The Company will (subject to Shareholder approval) issue to Eligible Shareholders up to 20,000,000 SPP Shares at $0.05 per SPP Share.

ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12 month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12 month period (**15% Placement Capacity**).

Approval under ASX Listing Rule 7.1 is being sought for the issue of the SPP Shares as:

- the exception to ASX Listing Rule 7.1 in ASX Listing Rule 7.2, Exception 5 does not apply to shares issued under a securities purchase plan that do not comply with the pricing conditions; and

- the number of SPP Shares exceeds the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- a person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
    - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
    - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

9. Resolution 6(b): Authority to issue SPP Options under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

" That, conditional on the approval of Resolution 6(a), for the purposes of ASX Listing Rule 7.1 and for all other purposes, Shareholders approve and authorise the Company to issue up to 20,000,000 SPP Options and, upon exercise of those SPP Options, the acquisition of the ordinary shares underlying those SPP Options, on the terms and conditions set out in the Explanatory Statement.”

Short explanation

The Company will (subject to Shareholder approval) issue to Eligible Shareholders up to 20,000,000 SPP Options at an exercise price of $0.0625 per SPP Option (to be exercised on or before the date that is 3 years following their issue).

ASX Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12 month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12 month period (**15% Placement Capacity**).

Approval under ASX Listing Rule 7.1 is being sought for the issue of the SPP Options as:

- the exception to ASX Listing Rule 7.1 in ASX Listing Rule 7.2, Exception 5 does not apply to options attaching to shares issued under a securities purchase plan; and
- the number of SPP Options exceeds the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- a person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

10. Resolution 7: Authority to issue Broker Options under ASX Listing Rule 7.1

To consider and, if thought fit, pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve and authorise the Company to issue 8,089,672 Broker Options and, upon exercise of those Broker Options, the acquisition of the ordinary shares underlying those Broker Options, on the terms and conditions set out in the Explanatory Statement."

Short explanation

The Company will (subject to Shareholder approval) issue the 8,089,672 Broker Options to the Joint Lead Managers and Latimer Partners, at an exercise price of $0.075 per Broker Option (to be exercised on or before the date that is 3 years following their issue).

Listing Rule 7.1 provides that a company must not, subject to specified exceptions, issue or agree to issue more Equity Securities (which includes shares) during any 12 month period than that amount which represents 15% of the number of fully paid ordinary securities on issue at the commencement of that 12 month period (**15% Placement Capacity**).

Approval under ASX Listing Rule 7.1 is being sought as the Broker Options (and the Shares to be issued upon exercise of those Broker Options) exceeds the 15% Placement Capacity.

Voting Exclusion Statement

The Company will disregard any votes cast in favour of this Resolution by or on behalf of:

- the Joint Lead Managers, Latimer Partners and any other person who is expected to participate in, or who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity); or
- an associate of that person or persons.

However, this does not apply to a vote cast in favour of the Resolution by:

- a person or proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- the Chair of the General Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
  - the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
  - the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

OTHER BUSINESS

To transact any other business which may be brought forward in accordance with the Company's constitution.

Section C – How to vote

1. How to vote

If you are entitled to vote at the General Meeting, you may vote by attending the General Meeting in person or by attending the meeting by proxy.

Please note that if you intend to attend the meeting, you will need your shareholder number (which can be found on your Proxy Form) for verification purposes.

2. Your vote is important

The business of the General Meeting affects your shareholding and your vote is important.

3. Corporations

To vote at the General Meeting, a Shareholder that is a corporation must appoint an individual to act as its representative. The appointment must comply with section 250D of the Corporations Act.

A corporation may appoint a proxy.

4. Voting in person

You may attend the General Meeting and vote in person. To vote in person, attend the General Meeting on the date and at the time and place set out above.

5. Voting by proxy

All Shareholders who are entitled to participate in and vote at the General Meeting have the right to appoint a proxy to participate in the General Meeting and vote in their place. A proxy need not be a Shareholder and can be an individual or a body corporate.

A Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion, or number, of votes which each proxy is entitled to exercise. If no proportion or number is specified, each proxy may exercise up to half of the Shareholder's votes.

Shareholders and their proxies should be aware that:

(a) if a proxy votes, they must cast all directed proxies as directed; and

(b) any directed proxies which are not voted will automatically default to the Chair, which must vote the proxies as directed.

To vote by proxy, you must complete and lodge the Proxy Form using one of the following methods:

Online	Lodge the Proxy Form online at portal.automic.com.au/investor and follow the instructions. To use the online lodgement facility, Shareholders will need Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.

By post	Automic GPO Box 5193 Sydney NSW 2001
By email	meetings@automicgroup.com.au
In person	Automic Level 5, 126 Phillip Street Sydney NSW 2000

For details on how to complete and lodge the Proxy Form, please refer to the instructions on the Proxy Form.

For your proxy appointment to be effective, it must be received by the Company not less than 48 hours before the General Meeting (i.e. by 1:00pm AEST (Brisbane time) on Wednesday, 22 July 2026). Proxy Forms received later than this time will be invalid.

You can direct your proxy how to vote (i.e. to vote ‘for’ or ‘against’, or to ‘abstain’ from voting on, each Resolution) by following the instructions either online or on the Voting Form. A proxy may decide whether to vote on an item of business, except where the proxy is required by law or the Company's constitution to vote, or abstain from voting in his or her capacity as proxy. If a proxy is directed how to vote on an item of business, the proxy may only vote on the item as directed. If a proxy is not directed how to vote on an item of business, the proxy may vote as he or she thinks fit.

If you are entitled to cast two or more votes, you may appoint two proxies and you may specify the proportion or number of votes that each proxy is appointed to exercise. If your appointment does not specify the proportion or number of your voting rights, each proxy may exercise half your votes (disregarding fractions).

If you appoint the Chair as your proxy but do not direct the Chair on how to vote, then by completing and submitting your voting instructions you are expressly authorising the Chair to vote in favour of each item of business, even where an item of business is directly or indirectly connected to the remuneration of a member of the key management personnel of the Company. The Chair intends to vote all available (including undirected) proxies in favour of all Resolutions, subject to the applicable voting exclusions and prohibitions.

You cannot lodge a direct vote and appoint a proxy for the same voting rights. The appointment of one or more duly appointed proxies will not preclude a Shareholder from attending the General Meeting and voting personally. If the Shareholder votes on a Resolution, the proxy must not vote as the Shareholder’s proxy on that Resolution.

6. Eligibility to vote

The Directors have determined pursuant to Regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) that the persons eligible to vote at the General Meeting are those that are registered Shareholders at 7:00pm (Brisbane time) on 22 July 2026. If you are not the registered holder of a relevant Share at that time you will not be entitled to vote in respect of that Share.

7. Voting procedure – on a poll

Every question arising at this General Meeting will be decided on a poll. Upon a poll, every person entitled to vote who is present at the meeting or by proxy will have one vote for each voting share held by that person.

8. Enquiries

For all enquiries, please contact the Company Secretary, James Heath, by email at james.heath@microba.com.

Section D – Explanatory Statement

This Explanatory Statement forms part of the Notice of General Meeting convening the General Meeting of Shareholders of the Company to be held commencing at 1:00pm AEST (Brisbane time) on Friday, 24 July 2026 at Thomsons, Level 28, 1 Eagle Street, Brisbane QLD 4000.

Refer to **Section C** for details on how to attend and vote at the General Meeting.

This Explanatory Statement is to be read in conjunction with the Notice of General Meeting.

Purpose

The purpose of this Explanatory Statement is to provide information which the Directors believe is material to Shareholders in deciding whether or not to pass the Resolutions to be put forward in the General Meeting.

The Directors recommend Shareholders read the Notice of General Meeting and this Explanatory Statement in full before making any decisions relating to the Resolutions contained in the Notice of General Meeting.

Defined terms

Terms used in this Explanatory Statement have the meaning given to them in the Glossary in **Section A** of this Notice of General Meeting & Explanatory Statement in which this Explanatory Statement is contained.

GENERAL INFORMATION

1 Resolution 1: Ratification of Tranche 1 Placement Shares issued under ASX Listing Rule 7.1

1.1 General

On 12 June 2026, the Company announced a Placement to raise approximately $5.0 million through the issue of Shares to sophisticated and professional investors (as described in section 708 of the Corporations Act) at an offer price of $0.05 per Share (**Placement**), with Morgans Corporate Limited and Canaccord Genuity (Australia) Limited acting as the Joint Lead Managers.

The Placement is to occur in two tranches.

(a) Tranche 1 of the Placement (**Tranche 1 Placement**) involved the issue of 91,344,455 Shares (**Tranche 1 Placement Shares**) on 18 June 2026 to raise $4.567 million of which all Shares were issued under Listing Rule 7.1, without the need for Shareholder approval within the Company's 15% annual limit. The ratification for the issue of the Tranche 1 Placement Shares is the subject of Resolution 1.

(b) Tranche 2 of the Placement (**Tranche 2 Placement**) involves the proposed issue of up to 8,659,785 Shares (**Tranche 2 Placement Shares**) to raise a further $432,989. The issue of the Tranche 2 Placement Shares is the subject of Resolutions 2, 4(a) and 5(a).

(c) In addition, the Tranche 1 Placement and Tranche 2 Placement involve the issue of Placement Options, consisting of the Tranche 1 Placement Options and Tranche 2 Placement Options (proposed to be issued following approval of Resolution 3 at the General Meeting) on the basis that for every one (1) Placement Share issued, one (1) free attaching Placement Option would be issued exercisable at $0.0625 per Placement Option on and from the date of issue until the date that is 3 years following their issue. The issue of the Tranche 1 Placement Options and the Tranche 2 Placement Options is the subject of Resolutions 3, 4(b) and 5(b).

The funds raised from the issue of the Tranche 1 Placement Shares will be used for the purposes set out below.

Resolution 1 seeks Shareholder approval and ratification pursuant to Listing Rule 7.4 for the prior issue of the 91,344,455 Tranche 1 Placement Shares issued under Listing Rule 7.1.

Resolution 1 is an ordinary resolution.

1.2 ASX Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, ASX Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

The issue of the Tranche 1 Placement Shares does not fit within any of these exceptions and, as it has not yet been approved by the Company's Shareholders, it effectively uses up part of the 15% limit in ASX Listing Rule 7.1, reducing the Company's capacity to issue further Equity Securities without Shareholder approval under ASX Listing Rule 7.1 for the 12 month period following the date of issue (**Issue Date**).

ASX Listing Rule 7.4 allows the Shareholders of a listed company to ratify an issue of Equity Securities after it has been made or agreed to be made. If they do, the issue is taken to have been approved under ASX Listing Rule 7.1 and so does not reduce the Company's capacity to issue further Equity Securities without Shareholder approval under that rule.

The Company wishes to retain as much flexibility as possible to issue additional Equity Securities into the future without having to obtain Shareholder approval for such issue under ASX Listing Rule 7.1.

To that end, Resolution 1 seeks Shareholder approval for the prior issue of the Tranche 1 Placement Shares under and for the purposes of ASX Listing Rule 7.4.

1.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolution 1 is passed, the issue of the Tranche 1 Placement Shares will be excluded in calculating the Company's 15% limit under ASX Listing Rule 7.1, effectively increasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the Issue Date.

If Resolution 1 is not passed, the issue of the Tranche 1 Placement Shares will be included in calculating the Company's 15% limit in ASX Listing Rule 7.1, effectively decreasing the number of Equity Securities it can issue without Shareholder approval over the 12-month period following the Issue Date.

1.4 Technical information required by ASX Listing Rule 7.5

For the purposes of Listing Rule 7.5, information regarding the issue of the Tranche 1 Placement Shares is provided as follows:

The names of the persons to whom the Company issued the securities:	The 91,344,455 Tranche 1 Placement Shares were issued to sophisticated investors who are exempt from the disclosure requirements under Chapter 6D of the Corporations Act identified and introduced by the Joint Lead Managers, none of whom is a Related Party of the Company and none of whom is a party to whom Listing Rule 10.11 would apply. For the avoidance of doubt, with the exception of Sonic Healthcare Limited, none of the recipients who were issued more than 1% of the Company’s current issued capital were: • a member of the key management personnel;

	• a substantial holder of the Company; • an adviser of the Company; or • an associate of any of the above.
The number and class of securities issued:	91,344,455 Tranche 1 Placement Shares were issued by the Company pursuant to Listing Rule 7.1. They are fully paid ordinary shares in the Company.
The date on which the securities were issued:	The 91,344,455 Tranche 1 Placement Shares were issued by the Company on 18 June 2026.
The issue price:	The issue price was $0.05 per Tranche 1 Placement Share, being approximately $4.567 million in total before costs.
If the securities are not fully paid ordinary securities, a summary of the material terms of the securities:	N/A, as the 91,344,455 Tranche 1 Placement Shares are fully paid ordinary shares of the Company ranking equally with all other fully paid ordinary shares of the Company.
The purpose of the issue, including the intended use of the funds raised:	Funds from the Tranche 1 Placement will be used for: • Core diagnostics growth across Australia and the UK; • Delivery of a category-defining new testing product; • Strengthening working capital; and • Costs of the Placement and SPP. A management fee of 3% and a selling fee of 3% was payable to the Joint Lead Managers on the proceeds from the Tranche 1 Placement.
If the securities were issued under an agreement, a summary of the material terms of the agreement:	The Tranche 1 Placement Shares were issued under a term sheet that detailed: • the price of each Tranche 1 Placement Share; • the Tranche 1 Placement Options will only be issued following Shareholder approval; and • the proposed issue date of each Tranche 1 Placement Share.
Voting exclusion statement:	A voting exclusion statement is contained in Resolution 1.

1.5 Recommendation and voting requirements

The Directors recommend that Shareholders approve Resolution 1.

Resolution 1 of the General Meeting is an ordinary resolution and so requires the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after the Resolution. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolution 1.

2 Resolution 2: Authority to issue Tranche 2 Placement Shares under ASX Listing Rule 7.1

2.1 General

Refer to the information in paragraph 1.1 for the background to this Resolution.

Resolution 2 seeks Shareholder approval pursuant to Listing Rule 7.1 for the issue of 8,659,785 Tranche 2 Placement Shares.

The funds raised from the issue of the Tranche 2 Placement Shares will be used for the purposes set out below.

The Tranche 2 Placement Shares, the subject of this Resolution, includes those Tranche 2 Placement Shares proposed to be subscribed for by Related Parties of the Company. The approval for the issue of those Tranche 2 Placement Shares are also subject to approval under Resolutions 4(a) and 5(a) for the purposes of ASX Listing Rule 10.11.

Resolution 2 is an ordinary resolution.

2.2 ASX Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

The proposed issue of the Tranche 2 Placement Shares does not fall within any of the exceptions under Listing Rule 7.2 and exceeds the 15% limit in ASX Listing Rule 7.1. It therefore requires the approval of the Company's Shareholders under ASX Listing Rule 7.1.

Resolution 2 seeks the required Shareholder approval for the issue of the Tranche 2 Placement Shares under and for the purposes of ASX Listing Rule 7.1.

2.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolution 2 is passed, the Company will be able to proceed with the issue of the Tranche 2 Placement Shares. In addition, the issue of the Tranche 2 Placement Shares will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If Resolution 2 is not passed and Resolution 1 is also not passed, the Company will not be able to proceed with the issue of the Tranche 2 Placement Shares.

If Resolution 2 is not passed and Resolution 1 is passed, the Company may proceed with the issue of the Tranche 2 Placement Shares up to the available placement capacity of the Company.

2.4 Technical information required by Listing Rule 7.3

For the purposes of Listing Rule 7.3, information regarding the issue of the Tranche 2 Placement Shares is provided as follows:

The names of the persons to whom the Company will issue the securities:	The Tranche 2 Placement Shares will be issued to sophisticated and professional investors. Those Tranche 2 Placement Shares proposed to be issued to Related Parties or associates of Related Parties of the Company, are also subject to approval under ASX Listing Rule 10.11 under Resolutions 4(a) and 5(a).
The number and class of securities to be issued:	The maximum number of Tranche 2 Placement Shares that the Company may issue under the Placement is 8,659,785 Tranche 2 Placement Shares. They will be fully paid ordinary shares in the Company.
The date on which the securities are proposed to be issued:	The Tranche 2 Placement Shares will be issued no later than three months after the date of the General Meeting (or such later date to the extent permitted by an ASX waiver or modification of the Listing Rules). It is intended that the Tranche 2 Placement Shares will be issued on or around 29 July 2026.
The issue price:	The Tranche 2 Placement Shares will be issued at $0.05 per Tranche 2 Placement Share, being $432,989 in total before costs.

If the securities are not fully paid ordinary securities, a summary of the material terms of the securities:	N/A, as the Tranche 2 Placement Shares are to be fully paid ordinary shares of the Company ranking equally with all other fully paid ordinary shares of the Company.
The purpose of the issue, including the intended use of the funds raised:	Funds from the Tranche 2 Placement will be used for: • Core diagnostics growth across Australia and the UK; • Delivery of a category-defining new testing product; • Strengthening working capital; and • Costs of the Placement and SPP. A management fee of 3% and a selling fee of 3% will be payable to the Joint Lead Managers on the proceeds from the Tranche 2 Placement.
If the securities are being issued under an agreement, a summary of the material terms of the agreement:	The Tranche 2 Placement Shares were issued under a term sheet that detailed: • the price of each Tranche 2 Placement Share; • the Tranche 2 Placement Options will only be issued following Shareholder approval; and • the proposed issue date of each Tranche 2 Placement Share.
Voting exclusion statement	A voting exclusion statement is contained in Resolution 2.

2.5 Recommendation and voting requirements

The Directors recommend that Shareholders approve Resolution 2.

Resolution 2 of the General Meeting is an ordinary resolution and so requires the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after the Resolution. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolution 2.

3 Resolution 3: Authority to issue Placement Options (consisting of the Tranche 1 Placement Options and Tranche 2 Placement Options) under ASX Listing Rule 7.1

3.1 General

Refer to the information in paragraph 1.1 for the background to this Resolution.

Pursuant to the Placement, and subject to Shareholder approval, the Company intends to issue 100,004,240 Placement Options which are free attaching to the Placement Shares on the basis of one (1) free Placement Option for every one (1) Placement Share subscribed for. The Placement Options consist of:

(a) 91,344,455 Tranche 1 Placement Options, which were free attaching to the Tranche 1 Placement Shares; and

(b) 8,659,785 Tranche 2 Placement Options, which are free attaching to the Tranche 2 Placement Shares.

The funds raised from the Placement Options will be used for the purposes set out below.

The Company will not apply for the Placement Options to be quoted on the ASX.

The Placement Options, the subject of this Resolution, includes those Placement Options to be issued to a Related Party of the Company. The approval for the issue of those Placement Options are also subject to Shareholder approval under Resolutions 4(b) and 5(b) for the purposes of ASX Listing Rule 10.11.

Resolution 3 is an ordinary resolution.

3.2 ASX Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

The proposed issue of the Placement Options does not fall within any of the exceptions under Listing Rule 7.2 and exceeds the 15% limit in ASX Listing Rule 7.1. It therefore requires the approval of the Company's Shareholders under ASX Listing Rule 7.1.

Resolution 3 seeks the required Shareholder approval for the issue of the Placement Options under and for the purposes of ASX Listing Rule 7.1.

3.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolution 3 is passed, the Company will be able to proceed with the issue of the Placement Options (consisting of both the Tranche 1 Placement Options and the Tranche 2 Placement Options). In addition, the issue of the Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If Resolution 3 is not passed, the Company will not be able to proceed with the issue of the Placement Options.

3.4 Technical information required by Listing Rule 7.3

For the purposes of Listing Rule 7.3, information regarding the issue of the Placement Options is provided as follows:

The names of the persons to whom the Company will issue the securities:	The Placement Options will be issued to sophisticated and professional investors. Those Placement Options proposed to be issued to Related Parties or associates of Related Parties of the Company, are also the subject of approval under ASX Listing Rule 10.11 under Resolutions 4(b) and 5(b).
The number and class of securities to be issued:	The maximum number of Placement Options that the Company may issue under the Placement is 100,004,240 Placement Options. One fully paid ordinary share in the Company will be allocated in relation to each exercised Placement Option upon payment of the exercise price.
The date on which the securities are proposed to be issued:	The Placement Options will be issued no later than three months after the date of the General Meeting (or such later date to the extent permitted by an ASX waiver or modification of the Listing Rules). It is intended that the Placement Options will be issued on 29 July 2026.
The issue price:	The Placement Options will be issued at an issue price of $nil per Placement Option as they are free attaching on the basis of one (1) free Placement Option for every one (1) Placement Share subscribed for.
If the securities are not fully paid ordinary securities, a summary of the material terms of the securities:	The Placement Options are to be issued under a prospectus issued under section 713 of the Corporations Act and are to be issued on the basis of one (1) Placement Option for every one (1) Placement Share issued.

	The prospectus was lodged with ASIC on or around 19 June 2026 and is available on the Company's website and on the ASX. Refer to **Schedule 1** for a summary of the terms of issue of the Placement Options. Each Placement Option is exercisable at $0.0625 per Placement Option on and from the date of issue and expires 3 years following their issue.
The purpose of the issue, including the intended use of the funds raised:	No funds will be raised given that the Placement Options will be issued at an issue price of $nil per Placement Option.
If the securities are being issued under an agreement, a summary of the material terms of the agreement:	The Placement Options are to be issued under a prospectus issued under section 713 of the Corporations Act that detailed: • the price of each Placement Share; • the proposed issue date of each Placement Option; and • that for every one (1) Placement Share issued, one (1) free attaching Placement Option would be issued exercisable at $0.0625 per Placement Option on and from the date of issue until the date that is 3 years following their issue. The prospectus was lodged with ASIC on or around 19 June 2026 and is available on the Company's website and on the ASX.
Voting exclusion statement	A voting exclusion statement is contained in Resolution 3.

3.5 Recommendation and voting requirements

The Directors recommend that Shareholders approve Resolution 3.

Resolution 3 of the General Meeting is an ordinary resolution and so requires the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after the Resolution. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolution 3.

4 Resolution 4(a), Resolution 4(b), Resolution 5(a) and Resolution 5(b) (inclusive) – Authority to issue Tranche 2 Placement Shares and Tranche 2 Placement Options to Related Parties under ASX Listing Rule 10.11

4.1 General

Refer to the information in paragraph 1.1 for the background to these Resolutions.

Directors, Mr Pasquale Rombola and Professor Ian Frazer (or their respective nominees), wish to participate in the Placement by subscribing for an aggregate 1,450,000 Tranche 2 Placement Shares and 1,450,000 Tranche 2 Placement Options.

Resolutions 4(a) and 4(b) and Resolutions 5(a) and 5(b) seek Shareholder approval for the issue of a total of 1,450,000 Tranche 2 Placement Shares and a total of 1,450,000 Tranche 2 Placement Options under the Placement to Mr Pasquale Rombola and Professor Ian Frazer (or their nominees) (**Placement Participation**).

4.2 Regulatory requirements

Chapter 2E of the Corporations Act

For a public company, or an entity that the public company controls, to give a financial benefit to a Related Party of the public company, the public company or entity must:

(a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and

(b) give the benefit within 15 months following such approval,

unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.

The issue of the Tranche 2 Placement Shares and Tranche 2 Placement Options constitutes giving a financial benefit and each of Mr Pasquale Rombola and Professor Ian Frazer are Related Parties of the Company by virtue of being Directors.

The Directors (other than Mr Pasquale Rombola who has a material personal interest in Resolutions 4(a) and 4(b)) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of Resolutions 4(a) and 4(b) because the Tranche 2 Placement Shares and Tranche 2 Placement Options will be issued to Mr Pasquale Rombola on the same terms as Tranche 2 Placement Shares and Tranche 2 Placement Options issued to non-Related Party participants in the Placement and, as such, the giving of the financial benefit is on arm's length terms.

The Directors (other than Professor Ian Frazer who has a material personal interest in Resolutions 5(a) and 5(b)) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of Resolutions 5(a) and 5(b) because the Tranche 2 Placement Shares and Tranche 2 Placement Options will be issued to Professor Ian Frazer on the same terms as Tranche 2 Placement Shares and Tranche 2 Placement Options issued to non-Related Party participants in the Placement and, as such, the giving of the financial benefit is on arm's length terms.

ASX Listing Rule 10.11

ASX Listing Rule 10.11 also requires shareholder approval to be obtained where an entity issues, or agrees to issue, securities to a director of the entity, an associate of the director, or a person whose relationship with the entity, director or associate of the director is, in ASX's opinion, such that approval should be obtained, unless an exception in ASX Listing Rule 10.12 applies.

As the Placement Participation involves the issue of Tranche 2 Placement Shares and Tranche 2 Placement Options to Related Parties of the Company, Shareholder approval pursuant to ASX Listing Rule 10.11 is required unless an exception applies. It is the view of the Directors that none of the exceptions set out in ASX Listing Rule 10.12 apply to the current circumstances.

4.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolutions 4(a) and 4(b) are passed, the Company will be able to proceed with the issue of the 1,250,000 Tranche 2 Placement Shares and 1,250,000 Tranche 2 Placement Options to Mr Pasquale Rombola. In addition, the issue of those Tranche 2 Placement Shares and Tranche 2 Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If Resolutions 5(a) and 5(b) are passed, the Company will be able to proceed with the issue of the 200,000 Tranche 2 Placement Shares and 200,000 Tranche 2 Placement Options to Professor Ian Frazer. In addition, the issue of those Tranche 2 Placement Shares and Tranche 2 Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If any of Resolutions 4(a) or 4(b) are not passed, the Company will not be able to proceed with the issue of the 1,250,000 Tranche 2 Placement Shares or 1,250,000 Tranche 2 Placement Options (as relevant) to Mr Pasquale Rombola.

If any of Resolutions 5(a) or 5(b) are not passed, the Company will not be able to proceed with the issue of the 200,000 Tranche 2 Placement Shares or 200,000 Tranche 2 Placement Options (as relevant) to Professor Ian Frazer.

Approval pursuant to ASX Listing Rule 7.1 is not required in order to issue the Tranche 2 Placement Shares and Tranche 2 Placement Options to Mr Pasquale Rombola and Professor Ian Frazer as approval is being obtained under ASX Listing Rule 10.11. Accordingly, under ASX Listing Rule 7.2, Exception 14, the issue of Tranche 2 Placement Shares and Tranche 2 Placement Options to Mr Pasquale Rombola and Professor Ian Frazer (or their nominees) will not be included in the 15% calculation of the Company's annual placement capacity pursuant to ASX Listing Rule 7.1.

4.4 Information required pursuant to ASX Listing Rule 10.13

The following information in regards to the Placement Participation is provided to satisfy the requirements of ASX Listing Rule 10.13 (being the information required to be disclosed for the purposes of ASX Listing Rule 10.11).

The names of the persons to whom the Company will issue the securities:	The Tranche 2 Placement Shares and Tranche 2 Placement Options are proposed to be issued to Mr Pasquale Rombola and Professor Ian Frazer (or their respective nominees).
Category of Placement Participants:	Each of Mr Pasquale Rombola and Professor Ian Frazer are Directors of the Company and, consequently, are Related Parties. This means that they fall within the category in ASX Listing Rule 10.11.1. Their nominees would fall within the category in ASX Listing Rule 10.11.4. The issue is not intended to remunerate or incentivise any of these Directors.
Number and class of securities to be issued:	A maximum of 1,450,000 of the Tranche 2 Placement Shares and 1,450,000 of the Tranche 2 Placement Options will be issued comprising of: • 1,250,000 Tranche 2 Placement Shares and 1,250,000 Tranche 2 Placement Options to Mr Pasquale Rombola (or his nominee) which are the subject of Resolution 4(a) and Resolution 4(b); and • 200,000 Tranche 2 Placement Shares and 200,000 Tranche 2 Placement Options to Professor Ian Frazer (or his nominee) which are the subject of Resolution 5(a) and Resolution 5(b). One fully paid ordinary share in the Company will be allocated in relation to each Placement Option which is exercised upon payment of the exercise price.
Price of the securities:	The 1,450,000 Tranche 2 Placement Shares will be issued for $0.05 per Tranche 2 Placement Share. The Placement Options are issued for nil consideration and are issued on the basis of one (1) Placement Option for every one (1) Tranche 2 Placement Share issued.
If the securities are not fully paid ordinary securities, a summary of the material terms of the securities:	The Tranche 2 Placement Shares comprise fully paid ordinary shares of the Company ranking equally with all other fully paid ordinary shares of the Company. The Placement Options are exercisable at $0.0625 per Placement Option on and from the date of issue until the date that is 3 years following their issue. Refer to **Schedule 1** for a summary of the terms of issue of the Placement Options.
Date by which the securities will be issued:	The Tranche 2 Placement Shares and Tranche 2 Placement Options are intended to be issued on or around 29 July 2026 but in any event, no later than 1 month after the date of the General Meeting.

The purpose of the issue, including the intended use of the funds raised:	Funds from the Tranche 2 Placement will be used for: • Core diagnostics growth across Australia and the UK; • Delivery of a category-defining new testing product; • Strengthening working capital; and • Costs of the Placement and SPP.
If the securities were issued under an agreement, a summary of the material terms of the agreement:	The Tranche 2 Placement Shares are to be issued under a term sheet that detailed: • the price of each Tranche 2 Placement Share; and • the proposed issue date of each Tranche 2 Placement Share; and • that for every one (1) Placement Share issued, one (1) free attaching Placement Option would be issued exercisable at $0.0625 per Placement Option and from the date of issue until the date that is 3 years following their issue. The Tranche 2 Placement Options are to be issued under a prospectus issued under section 713 of the Corporations Act. The prospectus was lodged on or around 19 June 2026 and is available on the Company's website.
Voting exclusion statement:	Voting exclusion statements are contained in Resolutions 4(a) and 4(b) and Resolutions 5(a) and 5(b).

4.5 Recommendation and voting requirements

The Directors (with the exception of Mr Pasquale Rombola and Professor Ian Frazer) recommend that Shareholders approve Resolutions 4(a) and 4(b) and Resolutions 5(a) and 5(b).

Resolutions 4(a) and 4(b) and Resolutions 5(a) and 5(b) of the General Meeting are ordinary resolutions and so require the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after each of the Resolutions. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolutions 4(a) and 4(b) and Resolutions 5(a) and 5(b).

5 Resolution 6(a) and Resolution 6(b): Authority to issue SPP Shares and SPP Options under ASX Listing Rule 7.1

5.1 General

Pursuant to the SPP, and subject to Shareholder approval, the Company intends to issue up to 20,000,000 SPP Shares and 20,000,000 SPP Options which are free attaching to the SPP Shares on the basis of one (1) free SPP Option for every one (1) SPP Share subscribed for.

The funds raised from the SPP will be used for the purposes set out below.

Resolution 6(a) relates to the 20,000,000 SPP Shares and Resolution 6(b) relates to the 20,000,000 SPP Options. Both are ordinary resolutions.

5.2 ASX Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

The proposed issue of the SPP Shares and SPP Options does not fall within any of the exceptions in Listing Rule 7.2 and exceeds the 15% limit in ASX Listing Rule 7.1. They therefore require the approval of the Company's Shareholders under ASX Listing Rule 7.1.

Resolution 6(a) and Resolution 6(b) seek the required Shareholder approval for the issue of the SPP Shares and SPP Options under and for the purposes of ASX Listing Rule 7.1. Resolution 6(a) and Resolution 6(b) are inter-conditional, meaning that both need to pass in order for one to pass.

5.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolution 6(a) and Resolution 6(b) are passed, the Company will be able to proceed with the issue of the SPP Shares and SPP Options. In addition, the issue of the SPP Shares and SPP Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If Resolution 6(a) and Resolution 6(b) are not passed, the Company will not be able to proceed with the issue of the SPP Shares and SPP Options.

5.4 Technical information required by Listing Rule 7.3

For the purposes of Listing Rule 7.3, information regarding the issue of the SPP Shares and SPP Options is provided as follows:

The names of the persons to whom the Company will issue the securities:	The SPP Shares and SPP Options will be issued to Eligible Shareholders of the Company. No Related Parties will take up any SPP Shares or SPP Options.
The number and class of securities to be issued:	The maximum number of SPP Shares and SPP Options that the Company may issue under the SPP is 20,000,000 SPP Shares and 20,000,000 SPP Options.
The date on which the securities are proposed to be issued:	The SPP Shares and SPP Options will be issued no later than three months after the date of the General Meeting (or such later date to the extent permitted by an ASX waiver or modification of the Listing Rules). It is expected that the SPP Shares and SPP Options will be issued on 29 July 2026 as detailed in the timetable for the SPP.
The issue price:	The SPP Shares will be issued for $0.05 per SPP Share. The SPP Options will be issued at an issue price of $nil per SPP Option as these are free attaching on the basis of one (1) free SPP Option for every one (1) SPP Share subscribed for.
If the securities are not fully paid ordinary securities, a summary of the material terms of the securities:	The SPP Shares are ordinary fully paid shares in the Company ranking equally with all other fully paid ordinary shares of the Company. Refer to **Schedule 1** for a summary of the terms of issue of the SPP Options. Each SPP Option is exercisable at $0.0625 per SPP Option and from the date of issue and expires 3 years following their issue.
The purpose of the issue, including the intended use of the funds raised	Proceeds from the SPP will be used for working capital purposes. No funds will be raised from the SPP Options, as they will be issued at an issue price of $nil per SPP Option. The SPP Options are being issued as a mechanism to raise funds following their exercise.
If the securities are being issued under an agreement, a summary of the material terms of the agreement:	The SPP Shares and SPP Options are to be issued under a prospectus issued under section 713 of the Corporations Act that detailed: • the price of each SPP Share, namely $0.05 per SPP Share; • the proposed issue date of each SPP Share and SPP Option; and • that for every one (1) SPP Share issued, one (1) free attaching SPP Option would be issued exercisable at $0.0625 per SPP Option on

	and from the date of issue until the date that is 3 years following their issue. The prospectus was lodged on or around 19 June 2026 and is available on the Company's website
Voting exclusion statement	Voting exclusion statements are contained in Resolution 6(a) and Resolution 6(b).

5.5 Recommendation and voting requirements

The Directors recommend that Shareholders approve Resolution 6(a) and Resolution 6(b).

Resolution 6(a) and Resolution 6(b) of the General Meeting are ordinary resolutions and so require the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after each of the Resolutions. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolution 6(a) and Resolution 6(b).

6 Resolution 7: Authority to issue Broker Options under ASX Listing Rule 7.1

6.1 General

Subject to Shareholder approval, the Company intends to issue 8,089,672 Broker Options to the Joint Lead Managers or their nominee(s).

The Broker Options will be issued on the terms detailed in Schedule 2.

Resolution 7 is an ordinary resolution.

6.2 ASX Listing Rule 7.1

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of Equity Securities that a listed company can issue without approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that period.

The proposed issue of the Broker Options does not fall within any of the exceptions in ASX Listing Rule 7.2 and exceeds the 15% limit in ASX Listing Rule 7.1. It therefore requires the approval of the Company's Shareholders under ASX Listing Rule 7.1.

Resolution 7 seeks the required Shareholder approval to the issue of the Broker Options under and for the purposes of ASX Listing Rule 7.1.

6.3 Effect of Shareholder approval (ASX Listing Rule 14.1A)

If Resolution 7 is passed, the Company will be able to proceed with the issue of the Broker Options. In addition, the issue of the Broker Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under ASX Listing Rule 7.1.

If Resolution 7 is not passed, the Company will not be able to proceed with the issue of the Broker Options.

6.4 Technical information required by Listing Rule 7.3

For the purposes of Listing Rule 7.3, information regarding the issue of the Broker Options is provided as follows:

The names of the persons to whom the Company will issue the securities:	The Broker Options will be issued to: • The Joint Lead Managers (or their nominees); and • Latimer Partners, Microba's corporate advisors.
The number and class of securities to be issued:	The maximum number of Broker Options that the Company may issue is 8,089,672 Broker Options.
The date on which the securities are proposed to be issued:	The Broker Options will be issued no later than three months after the date of the General Meeting (or such later date to the extent permitted by an ASX waiver or modification of the Listing Rules). It is intended that the Broker Options will be issued on 29 July 2026.
The issue price:	The Broker Options will be issued at an issue price of $nil. The Broker Options have an exercise price of $0.0750.
The terms of the securities:	Refer to **Schedule 2** for a summary of the terms of issue of the Broker Options.
The intended use of the funds raised:	No funds will be raised given that the Broker Options will be issued at an issue price of $nil.
If the securities are being issued under an agreement, a summary of the material terms of the agreement:	The Broker Options are being issued under a mandate with the Joint Lead Managers and Latimer Partners, which sets out: • the exercise price of the Broker Options; and • the proposed issue date of the Broker Options; and • that the Broker Options is exercisable on a 1:1 basis.
Voting exclusion statement	A voting exclusion statement is contained in Resolution 7.

6.5 Recommendation and voting requirements

The Directors recommend that Shareholders approve Resolution 7.

Resolution 7 of the General Meeting is an ordinary resolution and so requires the approval of more than 50% of the votes cast by Shareholders.

A voting exclusion statement is contained after the Resolution. Votes cast by Shareholders contrary to the voting exclusion statement will be disregarded.

The Chair of the General Meeting intends to vote all available undirected proxies in favour of Resolution 7.

Schedule 1

Terms of issue of Placement Options and SPP Options

Rights attaching to the Placement Options and SPP Options

The terms and conditions of the Placement Options and SPP Options are as follows:

Entitlement	Each Option entitles the holder (**Optionholder**) to subscribe for one fully paid ordinary share (**Share**) in the capital of the Microba Life Sciences Limited (**Company**) upon exercise of the Option.
Exercise Price	Each Option has an exercise price of $0.0625 per Option.
Expiry Date	The Options will expire at 5:00pm (Sydney time) on the date that is 3 years following their issue (**Expiry Date**). Any Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
Exercise Period	The Options are exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation of the Options	The Company does not intend to apply for official quotation of the Options at this time.
Transferability of the Options	The Options are freely transferrable.
Notice of Exercise	The Options may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency BPAY or electronic funds transfer. Any Notice of Exercise of an Option received by the Company will be deemed to be a notice of the exercise of that option as at the date of receipt.
Shares Issued on Exercise	Shares issued on exercise of the Options will rank equally with the then issued Shares of the Company.
Participation in New Issues	There are no participation rights or entitlements inherent in the Options and Optionholders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu of in satisfaction of dividends or by way of dividend reinvestment): • the number of Shares which must be issued on the exercise of an Option will be increased by the number of Shares which the Optionholder would have received if the Optionholder had exercised the Option before the record date for the Bonus issue; and • no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of Shares pro rata to existing Shareholders (other than as a Bonus issue to which the above will apply) there will be no adjustment of the Exercise Price of an Option or the number of Shares over which the Options are exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the Optionholders will be varied in accordance with the Listing Rules.

Schedule 2

Terms of issue of Broker Options

Rights attaching to the Broker Options

The terms and conditions of the Broker Options are as follows:

Entitlement	Each Broker Option entitles the holder (**Optionholder**) to subscribe for one fully paid ordinary share (**Share**) in the capital of the Microba Life Sciences Limited (**Company**) upon exercise of the Broker Option.
Exercise Price	Each Broker Option has an exercise price of a $0.075 per Option.
Expiry Date	The Broker Options will expire at 5:00pm (Sydney time) on the date that is 3 years following their issue (**Expiry Date**). Any Broker Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.
Exercise Period	The Broker Options are exercisable at any time and from time to time on or prior to the Expiry Date.
Quotation of the Options	The Company does not intend to apply for official quotation of the Broker Options at this time.
Transferability of the Options	The Broker Options are transferrable to a Related Body Corporate (as defined in the *Corporations Act 2001* (Cth)) of the Joint Lead Managers or Latimer Partners and otherwise, as approved by the Board.
Notice of Exercise	The Broker Options may be exercised by notice in writing to the Company in a form reasonably acceptable to the Company (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency BPAY or electronic funds transfer. Any Notice of Exercise of an Option received by the Company will be deemed to be a notice of the exercise of that option as at the date of receipt.
Shares Issued on Exercise	Shares issued on exercise of the Broker Options will rank equally with the then issued Shares of the Company.
Participation in New Issues	There are no participation rights or entitlements inherent in the Broker Options and Optionholders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Broker Options.
Adjustment for Bonus Issues of Shares	If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu of in satisfaction of dividends or by way of dividend reinvestment): • the number of Shares which must be issued on the exercise of a Broker Option will be increased by the number of Shares which the Optionholder would have received if the Optionholder had exercised the Broker Option before the record date for the bonus issue; and • no change will be made to the Exercise Price.
Adjustment for Entitlements Issue	If the Company makes an issue of Shares pro rata to existing Shareholders (other than as a Bonus issue to which the above will apply) there will be no adjustment of the Exercise Price of a Broker Option or the number of Shares over which the Broker Options are exercisable.
Adjustments for Reorganisation	If there is any reorganisation of the issued share capital of the Company, the rights of the Optionholders will be varied in accordance with the Listing Rules.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Microba Life Sciences Limited | ABN 82 617 096 652

Your proxy voting instruction must be received by **1:00pm (AEST) on Wednesday, 22 July 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS
The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: **https://investor.automic.com.au/#/home** Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY
If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING
Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS
You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY
You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS
Individual: Where the holding is in one name, the Shareholder must sign.
Joint holding: Where the holding is in more than one name, all Shareholders should sign.
Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.
Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.
Email Address: Please provide your email address in the space provided.
By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES
If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at https://automicgroup.com.au.

Lodging your Proxy Voting Form:

Online
Use your computer or smartphone to appoint a proxy at
https://portal.automic.com.au/investor/home or scan the QR code below using your smartphone
Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.

BY MAIL:
Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:
Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:
meetings@automicgroup.com.au

BY FACSIMILE:
+61 2 8583 3040

All enquiries to Automic:
WEBSITE:
https://automicgroup.com.au

PHONE:
1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

STEP 1 - How to vote

APPOINT A PROXY:

I/We being a Shareholder entitled to attend and vote at the General Meeting of Microba Life Sciences Limited, to be held at **1:00pm (AEST) on Friday, 24 July 2026 at Thomsons, Level 28, 1 Eagle Street, Brisbane QLD 4000** hereby:

Appoint the Chair of the Meeting (Chair) to vote in accordance with the following directions (or if no directions have been given, and subject to the relevant laws, as the Chair sees fit) at this meeting and at any adjournment thereof.

Please note: If you are not appointing the Chair of the Meeting as your proxy, please write in the box provided below the name of the person or body corporate you are appointing as your proxy. If the person so named is absent from the meeting, or if no person is named, the Chair will act on your behalf.

The Chair intends to vote undirected proxies in favour of all Resolutions in which the Chair is entitled to vote.
Unless indicated otherwise by marking the "for", "against" or "abstain" box you will be authorising the Chair to vote in accordance with the Chair's voting intention.

STEP 2 - Your voting direction

Resolutions		For	Against	Abstain
1	Ratification of Tranche 1 Placement Shares issued under ASX Listing Rule 7.1			
2	Authority to issue Tranche 2 Placement Shares under ASX Listing Rule 7.1			
3	Authority to issue Placement Options (consisting of the Tranche 1 Placement Options and Tranche 2 Placement Options) under ASX Listing Rule 7.1			
4a	Authority to issue Tranche 2 Placement Shares to a Related Party, Mr Pasquale Rombola, under ASX Listing Rule 10.11			
4b	Authority to issue Tranche 2 Placement Options to a Related Party, Mr Pasquale Rombola, under ASX Listing Rule 10.11			
5a	Authority to issue Tranche 2 Placement Shares to a Related Party, Professor Ian Frazer, under ASX Listing Rule 10.11			
5b	Authority to issue Tranche 2 Placement Options to a Related Party, Professor Ian Frazer, under ASX Listing Rule 10.11			
6a	Authority to issue SPP Shares under ASX Listing Rule 7.1			
6b	Authority to issue SPP Options under ASX Listing Rule 7.1			
7	Authority to issue Broker Options under ASX Listing Rule 7.1			

Please note: If you mark the abstain box for a particular Resolution, you are directing your proxy not to vote on that Resolution and your votes will not be counted in computing the required majority on a poll.

STEP 3 – Signatures and contact details

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name:

Email Address:

Contact Daytime Telephone

Date (DD/MM/YY)

/ /

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

AUTOMIC

MAP